HMGCR and myositis disease: Our calculated average incidence of anti-HMGCR IMNM in the current combined cohort, 2.9 cases/million/year, is higher than that reported from the Johns Hopkins myositis cohort (from 2002–2010, 2 cases/million/year) [9] and in England (in 2019, 1.94/million adults/year) [29].